MDS

Gilead’s Magrolimab ineffective, linked to increased risk of death in MDS patients
BioSpace
Mon, 06/17/24 - 11:39 am
Gilead Sciences
clinical trials
patient deaths
MDS
magrolimab
Roivant to Shutter MDS-Focused ‘Vant’ After Disappointing Phase I/II Trial Results
BioSpace
Wed, 02/14/24 - 10:57 am
Roivant
TVT-2001
MDS
Hemavant
Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS
BioSpace
Wed, 10/25/23 - 09:41 am
Servier
Tibsovo
MDS
FDA
Faron’s Clever-1 drug shows promise in blood cancers
Pharmaphorum
Wed, 10/11/23 - 10:01 am
Faron Pharmaceuticals
bexmarilimab
AML
MDS
clinical trials
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Fierce Biotech
Mon, 08/21/23 - 10:06 am
Gilead Sciences
MDS
magrolimab
clinical trials
AML
FDA starts speedy review of Servier's Tibsovo in MDS
Pharmaphorum
Thu, 08/17/23 - 09:58 am
Servier
IDH inhibitors
MDS
Tibsovo
FDA
priority reviews
Gilead drug acquired in $5B buyout fails key blood cancer trial
BioPharma Dive
Mon, 07/24/23 - 11:47 am
Gilead Sciences
M&A
oncology
clinical trials
magrolimab
MDS
Forty Seven
FDA Accepts sBLA of BMS' Reblozyl
Targeted Oncology
Mon, 05/1/23 - 10:01 pm
Bristol Myers Squibb
Reblozyl
FDA
MDS
anemia
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Tue, 08/23/22 - 10:35 am
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
Bristol Myers dusts off an old Celgene chemotherapy for use in children with a rare blood cancer
Endpoints
Mon, 05/23/22 - 06:51 pm
Bristol Myers Squibb
Celgene
chemotherapy
FDA
Vidaza
MDS
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Fierce Biotech
Mon, 02/14/22 - 12:05 pm
Hemavant
Roivant Sciences
Eisai
MDS
RVT-2001
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Fierce Biotech
Wed, 02/2/22 - 12:15 pm
Gilead Sciences
clinical trials
clinical hold
magrolimab
AML
MDS
Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022
Fierce Biotech
Fri, 10/29/21 - 10:35 am
Gilead Sciences
Forty Seven
magrolimab
MDS
How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market
Motley Fool
Thu, 07/29/21 - 11:12 am
AbbVie
Roche
Venclexta
MDS
breakthrough therapy
Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug
BioSpace
Wed, 07/21/21 - 08:41 pm
Magenta Therapeutics
AML
MDS
FDA
clinical hold
MGTA-117
Gilead gets FDA breakthrough therapy status for magrolimab in MDS
Pharmaceutical Business Review
Wed, 09/16/20 - 10:37 am
Gilead Sciences
FDA
MDS
magrolimab
breakthrough therapy
FDA Approves At-Home Oral Therapy for MDS
Xtalks
Sat, 07/11/20 - 11:51 am
FDA
Inqovi
MDS
CMML
Otsuka
Astex
Gilead trumpets data with newly-bought magrolimab in blood cancers
Pharmaforum
Sun, 05/31/20 - 11:53 pm
Gilead Sciences
ASCO 2020
Forty Seven
magrolimab
M&A
MDS
Gilead’s newly bought immunotherapy drug scores at ASCO
MedCity News
Fri, 05/29/20 - 12:30 pm
Gilead Sciences
ASCO 2020
magrolimab
clinical trials
AML
MDS
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Mon, 04/6/20 - 10:30 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS

Pages